Biocon gets USFDA nod for gSaxenda injection
Biocon just scored USFDA approval for its gSaxenda injection, a generic version of Saxenda, aimed at helping adults manage obesity or being overweight.
This is a big step for Biocon as it pushes further into the US market with a drug that works by boosting insulin and helping people feel full longer.
Biocon's CEO calls the approval 'defining milestone'
gSaxenda isn't new to the scene—it's based on a drug first approved in 2009 (EU); approved in the United States in 2010 for diabetes and later cleared for weight loss in adults.
The US market for these kinds of meds is already worth $127 million, so there's real potential here.
Biocon's CEO called the approval "marks a defining milestone" and says they're moving fast to launch in the US after rolling out in the UK (date not stated in source).
If you're interested in health tech or pharma breakthroughs, this is one to watch.